Rob Hill1, William L Dewey2, Eamonn Kelly1, Graeme Henderson1. 1. School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK. 2. Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298-0613, USA.
Abstract
BACKGROUND AND PURPOSE: Oxycodone, a prescription opioid, is a major drug of abuse, especially in the USA, and contributes significantly to opioid overdose deaths each year. Overdose deaths result primarily from respiratory depression. We have studied respiratory depression by oxycodone and have characterized how tolerance develops on prolonged exposure to the drug. We have investigated the role of PKC in maintaining tolerance and have examined whether ethanol or pregabalin reverses oxycodone-induced tolerance. EXPERIMENTAL APPROACH: Respiration was measured in male CD-1 mice by whole-body plethysmography. Mice were preinjected with oxycodone then implanted with mini-pumps (s.c.) delivering 20, 45 or 120 mg·kg-1 ·day-1 oxycodone for 6 days and subsequently challenged with oxycodone (3 mg·kg-1 , i.p.) or morphine (10 mg·kg-1 , i.p.) to assess the level of tolerance. KEY RESULTS: Oxycodone-treated mice developed tolerance to oxycodone and cross tolerance to morphine-induced respiratory depression. Tolerance was less with 20 mg·kg-1 ·day-1 than with 45 or 120 mg·kg-1 ·day-1 oxycodone treatment. At doses that do not depress respiration, ethanol (0.3 g·kg-1 ), pregabalin (20 mg·kg-1 ) and calphostin C (45 μg·kg-1 ) all reversed oxycodone-induced tolerance resulting in significant respiratory depression. Reversal of tolerance was less in mice treated with oxycodone (120 mg·kg-1 ·day-1 ). In mice receiving ethanol and calphostin C or ethanol and pregabalin, there was no greater reversal of tolerance than seen with either drug alone. CONCLUSION AND IMPLICATIONS: These data suggest that oxycodone-induced tolerance is mediated by PKC and that reversal of tolerance by ethanol or pregabalin may be a contributory factor in oxycodone overdose deaths.
BACKGROUND AND PURPOSE:Oxycodone, a prescription opioid, is a major drug of abuse, especially in the USA, and contributes significantly to opioid overdose deaths each year. Overdose deaths result primarily from respiratory depression. We have studied respiratory depression by oxycodone and have characterized how tolerance develops on prolonged exposure to the drug. We have investigated the role of PKC in maintaining tolerance and have examined whether ethanol or pregabalin reverses oxycodone-induced tolerance. EXPERIMENTAL APPROACH: Respiration was measured in male CD-1 mice by whole-body plethysmography. Mice were preinjected with oxycodone then implanted with mini-pumps (s.c.) delivering 20, 45 or 120 mg·kg-1 ·day-1 oxycodone for 6 days and subsequently challenged with oxycodone (3 mg·kg-1 , i.p.) or morphine (10 mg·kg-1 , i.p.) to assess the level of tolerance. KEY RESULTS:Oxycodone-treated mice developed tolerance to oxycodone and cross tolerance to morphine-induced respiratory depression. Tolerance was less with 20 mg·kg-1 ·day-1 than with 45 or 120 mg·kg-1 ·day-1 oxycodone treatment. At doses that do not depress respiration, ethanol (0.3 g·kg-1 ), pregabalin (20 mg·kg-1 ) and calphostin C (45 μg·kg-1 ) all reversed oxycodone-induced tolerance resulting in significant respiratory depression. Reversal of tolerance was less in mice treated with oxycodone (120 mg·kg-1 ·day-1 ). In mice receiving ethanol and calphostin C or ethanol and pregabalin, there was no greater reversal of tolerance than seen with either drug alone. CONCLUSION AND IMPLICATIONS: These data suggest that oxycodone-induced tolerance is mediated by PKC and that reversal of tolerance by ethanol or pregabalin may be a contributory factor in oxycodoneoverdose deaths.
Authors: Gregory J Pfister; Robert M Burkes; Brian Guinn; Jacquelene Steele; Robert R Kelley; Timothy L Wiemken; Mohamed Saad; Julio Ramirez; Rodrigo Cavallazzi Journal: J Crit Care Date: 2016-04-30 Impact factor: 3.425
Authors: Javier Llorente; Sarah Withey; Guadalupe Rivero; Margaret Cunningham; Alex Cooke; Kunal Saxena; Jamie McPherson; Sue Oldfield; William L Dewey; Chris P Bailey; Eamonn Kelly; Graeme Henderson Journal: Mol Pharmacol Date: 2013-05-28 Impact factor: 4.436
Authors: Zheng Dai; Marie A Abate; D Leann Long; Gordon S Smith; Theresa M Halki; James C Kraner; Allen R Mock Journal: Forensic Sci Int Date: 2020-05-31 Impact factor: 2.395
Authors: Elizabeth A Ibiloye; Jamie C Barner; Kenneth A Lawson; Karen L Rascati; Kirk E Evoy; Alyssa M Peckham Journal: Clin Drug Investig Date: 2021-02-12 Impact factor: 2.859
Authors: Louben Dorval; Brian I Knapp; Olufolake A Majekodunmi; Sophia Eliseeva; Jean M Bidlack Journal: Neuropharmacology Date: 2021-10-26 Impact factor: 5.250
Authors: Neil B Varshneya; Sherif H Hassanien; Melissa C Holt; David L Stevens; Nathan K Layle; Jonathon R Bassman; Donna M Iula; Patrick M Beardsley Journal: Biochem Pharmacol Date: 2021-10-19 Impact factor: 6.100
Authors: Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney Journal: Lancet Date: 2019-10-23 Impact factor: 79.321
Authors: Mohit Kumar; Jennifer R Rainville; Kori Williams; Joshua A Lile; Georgia E Hodes; Fair M Vassoler; Jill R Turner Journal: Neuropharmacology Date: 2021-01-22 Impact factor: 5.250